Iterum Therapeutics Plc (NASDAQ:ITRM) currently has a daily average trading volume of 411.36K but it saw 213453 shares traded in last market. With a market cap of 37.35M USD, the company’s current market price of $1.08 came rising about 2.86 while comparing to the previous closing price of $1.05. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.02 and as low as $0.81. In the recent trading on the day, stock has struck highest price mark of $1.05 while lowest mark touched by it was $1.1.
Taking a look at 20-day trading activity of Iterum Therapeutics Plc (ITRM) gives us an average price of $1.2005, while its current price level is -64.24% below from 52-week high level whereas it is 33.66% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.3257 while that of 200 days or SMA-200 reads an average of $1.3941. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.64% during that period while stretching the period over a month that increases to 6.60%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 32.83 which implies that the stock is in neutral territory.
H.C. Wainwright upgraded its recommendation for the stock as a “Buy” from “Neutral” on March 15, 2021 while assigning a price target of $2.50. RBC Capital Mkts issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $7 and $2.
Over the week, ITRM’s stock price is moving -1.82% down while it is -25.52% when we observe its performance for the past one month. Year-to-date it is -38.98% down and over the past year, the stock is showing a downside performance of -31.21%.
Currently, Iterum Therapeutics Plc’s total number of outstanding shares is 34.58M. Company’s return on investment (ROI) stands at -91.79% and return on equity (ROE) at -555.68%. Stock’s beta reads 2.87. Its return on asset (ROA) is -69.93% on average.
